Facebook
X
LinkedIn
Forward
49th Annual Carrell Krusen Neuromuscular Symposium (RP2702C)
This symposium is a clinical education experience for members of multidisciplinary teams who care for patients with rare, complex neuromuscular diseases including hereditary muscular dystrophies, motor neuron diseases, neuroimmunologic neuropathies and rare genetic disorders of muscle and nerve. Case presentations will include physical diagnosis and discussion of management and new therapies by participating experts. All discussions involve active participation by attendees. The educational format for this activity includes didactic lectures with in-depth Q&A, and panel discussions. The content of the program is identified and developed through a Call for Abstracts process. The 2027 keynote speaker, Diana Bharucha-Goebel, MD, Medical Director of the Gene Therapy Center of Excellence at Nationwide Children's Hospital, will present on the evolving landscape of AAV-mediated gene therapy for pediatric neuromuscular disease, including vector design, route of administration, and immune modulation strategies to optimize safety and efficacy in patients receiving gene replacement therapy.
Submit an Abstract
Help shape this year's conference by submitting an abstract! Open to all members of the interdisciplinary team.
Click HERE to submit an abstract!
The deadline for abstract submission is Monday, November 23, 2026.
Target Audience
- Primary Care providers
- Neurologists
- Nurses
- Advanced Practitioners
- Researchers
Learning Objectives
1. Discuss the principles of AAV-mediated gene transfer as applied to pediatric neuromuscular disease, including route of administration and immune modulation strategies used to optimize safety and efficacy.
2. Review outcome measures and trial-readiness considerations for ultra-rare neuromuscular conditions.
3. Identify practical considerations for patient selection, counseling, and post-treatment monitoring as gene therapies move into broader clinical use.
4. Discuss recent advances in the genetic diagnosis of neuromuscular disorders, in research and clinical practice and the latest developments in treatment such as gene replacement therapy, cell therapy and forms of RNA therapy.
5. Review the pathophysiology, genetic underpinnings, and current treatment strategies for metabolic myopathies
6. Recognize the clinical applications of results of imaging both MRI and ultrasound as well as histopathology in neuromuscular disorders.
Course summary
- 9.00 AMA
- 9.00 Attendance
The University of Texas Southwestern Medical Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physician
The University of Texas Southwestern Medical Center designates this live activity for a maximum of 9.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Non-Physician
The University of Texas Southwestern Medical Center certifies that non-physicians will receive an attendance certificate stating that they participated in the activity that was designated for 9.00 AMA PRA Category 1 Credits™.
Available Credit
- 9.00 AMA
- 9.00 Attendance
Price
To register:
- "Login" to your existing account or create an account in EthosCE, online learning management system, by selecting the "create an account" link.
- Once logged in, return to this course page, select the designated fee and click the "add to cart" button.
- In the following "checkout" pages you will verify and process your payment.
- After registration is completed, a confirmation will be sent by email.
A $25 handling fee will be deducted from cancellation refunds. Refund requests must be received by email at [email protected] by February 5, 2027. No refunds will be made thereafter.